About ALOXI®
FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
* Based on sNDA Approval in August 2007, the restriction on repeated dosing of ALOXI
within a 7-day interval was removed.
Indication
ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the
prevention of acute and delayed nausea and vomiting associated with initial and
repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting
associated with initial and repeat courses of highly emetogenic chemotherapy.
Important Safety Information
- Aloxi is contraindicated in patients known to have hypersensitivity to the drug
of any of its components
- Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting
include headache (9%) and constipation (5%)
ALOXI is available by prescription only.
The health information contained herein is provided for educational purposes only
and is not intended to replace discussions with a healthcare provider. All decisions
regarding patient care must be made with a healthcare provider, considering the
unique characteristics of the patient.
This site is intended for residents of the United States only. The products discussed
herein may have different product labeling in different countries.